Clinical Trial Update: Associated Genes With Atomoxetine Response in Attention Deficit Hyperactivity Disorder (ADHD) [Phase 4]

View source ↗

Summary

Phase 4 clinical trial update examining genetic factors that influence atomoxetine response in Attention Deficit Hyperactivity Disorder.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Attention Deficit Hyperactivity Disorder

Drugs mentioned

• Atomoxetine (Atomoxetine)

Snippet

Sponsor: Peking University | Conditions: Attention Deficit Hyperactivity Disorder | Phase 4 | Status: UNKNOWN